You are currently viewing the abstract.View Full Text
In this issue of Science Translational Medicine, Gasparian et al. use a clever cell-based screen to identify a family of DNA-binding small molecules—curaxins—that inhibit tumor cell growth and division. The curaxins’ mechanism of action pinpoints a new chromatin-remodeling factor as a therapeutic target for cancer.
Citation: G. F. Draetta, R. A. DePinho, Cancer Drug Discovery Faces the FACT. Sci. Transl. Med. 3, 95ps34 (2011).
- Copyright © 2011, American Association for the Advancement of Science